source
- Aclaris Therapeutics’ bosakitug fails Phase 2 eczema trial, TSLP program droppedAclaris Therapeutics announced that its experimental antibody bosakitug (ATI-045) did not meet the primary endpoint in a Phase 2 study for moderate-to-severe atopic dermatitis. The double‑blind Ad…
- Australian regulator seeks feedback on adding unique device IDs to medical device free‑sale certificatesAustralia’s Therapeutic Goods Administration (TGA) announced it is reviewing whether to include unique device identification (UDI) details on certificates of free sale that accompany medical device…